Detalhe da pesquisa
1.
Comparing the Use of Topical Therapy Along with Anti-IL-17 and Anti-IL-23 to Treat Moderate-to-Severe Psoriasis in the Routine Clinical Practice. / Comparación del uso de la terapia tópica combinada con anti-interleucina-17 y anti-interleucina-23 en la psoriasis moderada grave en la práctica clínica.
Actas Dermosifiliogr
; 2024 Feb 01.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-38307164
2.
Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain.
Actas Dermosifiliogr
; 115(1): 1-9, 2024 Jan.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-37429433
3.
Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain. / [Artículo traducido] Gravedad de la psoriasis, calidad de vida relacionada con la salud, productividad laboral y deterioro de la actividad en pacientes con psoriasis moderada a grave que reciben tratamiento sistémico: datos de la vida real de la práctica clínica en España.
Actas Dermosifiliogr
; 115(1): T1-T9, 2024 Jan.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-37923068
4.
Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study.
J Eur Acad Dermatol Venereol
; 2023 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37567861
5.
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
J Eur Acad Dermatol Venereol
; 36(10): 1774-1783, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35460287
6.
Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience. / Psoriasis moderada-grave en pacientes pediátricos y jóvenes: experiencia en el registro BIOBADADERM.
Actas Dermosifiliogr
; 113(4): 401-406, 2022 Apr.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-35428502
7.
Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results.
J Eur Acad Dermatol Venereol
; 35(2): 431-440, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32426889
8.
Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: the PROSE study population.
J Eur Acad Dermatol Venereol
; 34(11): 2548-2556, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32239541
9.
Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis.
J Eur Acad Dermatol Venereol
; 33(7): 1214-1223, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31037770
10.
The Utility of long-Term Number Needed to Treat to Evaluate Interleukin 17 and 23 Inhibitor Therapies in the Treatment of Moderate to Severe Plaque Psoriasis. / La utilidad del número necesario de pacientes a largo plazo a tratar para evaluar las terapias inhibidoras de las interleucinas 17 y 23 en el tratamiento de la psoriasis en placas de moderada a grave.
Actas Dermosifiliogr
; 115(4): 427-429, 2024 Apr.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-38056560
11.
[Translated article] The Utility of long-Term Number Needed to Treat to Evaluate Interleukin 17 and 23 Inhibitor Therapies in the Treatment of Moderate to Severe Plaque Psoriasis.
Actas Dermosifiliogr
; 115(4): T427-T429, 2024 Apr.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-38336245
12.
New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis.
Pharmacogenomics J
; 18(1): 70-75, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27670765
13.
IL17RA gene variants and anti-TNF response among psoriasis patients.
Pharmacogenomics J
; 18(1): 76-80, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27670766
14.
Recommendations for the management of comorbidity in hidradenitis suppurativa.
J Eur Acad Dermatol Venereol
; 32(1): 129-144, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28796920
15.
Position statement for the management of comorbidities in psoriasis.
J Eur Acad Dermatol Venereol
; 32(12): 2058-2073, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29992631
16.
Diagnostic approach to subcutaneous nodules in patients with neuroendocrine tumours treated with depot somatostatin analogs: a cross-sectional study.
J Eur Acad Dermatol Venereol
; 32(11): 1887-1892, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29377286
17.
Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice.
J Eur Acad Dermatol Venereol
; 37(12): e1480-e1482, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37471473
18.
Immune cells from patients with psoriasis are defective in inducing indoleamine 2,3-dioxygenase expression in response to inflammatory stimuli.
Br J Dermatol
; 176(3): 695-704, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27258822
19.
Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients.
J Eur Acad Dermatol Venereol
; 31(8): 1271-1284, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28419600
20.
Effectiveness and safety profile of secukinumab for the treatment of patients with generalized pustular psoriasis in daily practice.
J Eur Acad Dermatol Venereol
; 36(10): e849-e851, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35689497